Research programme: transdermal influenza virus vaccine - Altea Therapeutics

Drug Profile

Research programme: transdermal influenza virus vaccine - Altea Therapeutics

Alternative Names: Influenza vaccine skin patch - Altea Therapeutics; Influenza vaccine transdermal patch - Altea Therapeutics

Latest Information Update: 15 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Altea Therapeutics
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 12 Nov 2012 Nitto Denko acquires all assets of Altea Therapeutics
  • 09 Dec 2011 Discontinued for Influenza virus infections in USA (Transdermal)
  • 07 Jul 2008 Early research in Influenza virus infections in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top